Akebia Q2 2025 Earnings Preview
Source: SeekingAlpha
2025-08-06 12:15:34 ET
More on Akebia
- Akebia Therapeutics: Stock Is Trading At Fair Value Amid Robust Drug Adoption Into 2026
- Akebia Therapeutics: Finally Showing Potential, But Wait For Q2 Earnings Before Buying
- Akebia Therapeutics, Inc. (AKBA) Q1 2025 Earnings Call Transcript
- Akebia projects Vafseo rollout to double patient access by Q4 2025
- Seeking Alpha’s Quant Rating on Akebia
Read the full article on Seeking Alpha
For further details see:
Akebia Q2 2025 Earnings Preview
Akebia Therapeutics Inc.
NASDAQ: AKBA
AKBA Trading
2.89% G/L:
$1.425 Last:
2,079,511 Volume:
$1.41 Open:
AKBA Latest News
March 03, 2026 08:00:00 am
Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference
February 26, 2026 07:00:00 am
Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights
AKBA Stock Data
$399,375,819
257,405,013
0.93%
52
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
